Clinical Trial

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-03; most recent amendment 2025-02-16.
Status change: Not Yet Recruiting → Recruiting 2023-10-05
Trial Details
NCT Number NCT05977023
Lead Sponsor China Medical University Hospital
Collaborators: National Science and Technology Council
Conditions Bipolar I Disorder
Enrollment 90 participants
Start Date 2023-10-04
Primary Completion 2027-11 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-19